Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage
biopharmaceutical company focused on the development of oncology
therapeutics, today announced that it has expanded its management
team with the appointments of Joseph Bisaha, PhD as Vice President,
Clinical Operations and Project Management and David M. Jackson,
PhD as Vice President, Diagnostics. These additions to the
Company's team of highly experienced and skilled members are
expected to support the continued clinical development of Arno's
lead compound and personalized therapy onapristone and the
co-development of a companion diagnostic and other biomarkers with
various partners and collaborators.
Dr. Bisaha will be responsible for the planning, implementation
and daily operations of Arno's drug development projects, including
the ongoing clinical trials of onapristone, for which the Company
anticipates to soon enroll the first patient in a Phase I dose
escalation study. The Phase I trial will evaluate onapristone in
post-menopausal women with progesterone receptor (PR) positive
tumors, including breast, endometrial and others solid tumors. The
multi-site trial is expected to enroll a total of 60 patients in
France. With significant project planning experience, Dr. Bisaha
will lead the operational aspects of Arno's clinical development
program, working closely with Chief Medical Officer Alex Zukiwski,
M.D. to prepare clinical plans and manage the programs.
Dr. Jackson will manage various biomarker and companion
diagnostic (CDx) co-development partnerships in support of
onapristone. Dr. Jackson specializes in personalized medicine and
companion diagnostics, including drug and diagnostic
co-development, commercialization and investment, and has more than
13 years' experience with healthcare technology companies and
healthcare investment firms with an emphasis on paradigm-changing
technologies filling unmet market opportunities.
Glenn Mattes, President and Chief Executive Officer of Arno
Therapeutics, remarked, "These key strategic hires position Arno to
execute our strategy of advancing the clinical development
onapristone and the CDx development. Joseph and David are highly
accomplished scientific leaders, who will significantly strengthen
our team through their unique blend of knowledge, experience and
skills. With their contributions, we are poised for success and I
look forward to working with them as we continue advancing toward
our near- and longer-term objectives."
Prior to his appointment as Vice President, Clinical Operations
and Project Management, Dr. Bisaha was a Clinical Research
Consultant with Kaizen Clinical Services Inc, where he was
responsible for Arno's Clinical Operations and Project Management
activities. During his 17 year career, he has held various drug
development positions of increasing responsibility including
Associate Vice President, Project Management at ImClone Systems,
Inc., Senior Director, Clinical Research & Drug Development at
Ono Pharma USA Inc., Director, Clinical Operations, at Celgene
Corporation and Director, Project Management at Yamanouchi Pharma
America, Inc. Dr. Bisaha earned his B.A. in biochemistry at
Rutgers University, his Ph.D. in cell and developmental biology at
Cornell University and was a postdoctoral fellow at The Rockefeller
University.
Dr. Jackson joins Arno Therapeutics as Vice President,
Diagnostics. Prior to joining Arno, he was Vice President, Business
Development at PrimeraDx, Inc., a molecular diagnostic manufacturer
and companion diagnostic development partner, where he was
responsible for corporate partnerships and contracts; in- and
out-licensing; sell-side BD, design, execution and oversight of
companion diagnostic partnership programs. Previously, Dr. Jackson
was Senior Director, Companion Diagnostics Partnerships at QIAGEN
Manchester (formerly DxS, Ltd.), and since 2007, has worked as an
independent development and commercialization consultant to bio and
pharmaceutical drug developers, IVD manufacturers and specialized
laboratories in the area of personalized medicine and companion
diagnostics. Additionally, Dr. Jackson was a senior healthcare
analyst covering molecular diagnostics and personalized medicine at
ThinkPanmure and an analyst at Research Corporation Technologies, a
healthcare-focused venture capital firm. Dr. Jackson earned a Ph.D.
in Human Physiology & Medicine from Boston University School of
Medicine and a B.S. in Biological Sciences from Texas A&M
University.
About Onapristone
Onapristone has the potential to be the first approved
anti-progestin for oncology indications and provide
chemotherapy-sparing treatment to cancer patients who express a
specific biomarker, as detected by a companion diagnostic under
development. Onapristone is an oral, anti-progestin hormone blocker
that has been shown in previous clinical trials to have anti-tumor
activity in patients with breast cancer. Onapristone appears to
have a unique ability to block the activation of the progesterone
receptor, which is believed to be a mechanism that may inhibit the
growth of breast, endometrial and other tumors. The activated form
of the progesterone receptor (APR) has the potential to function as
a biomarker of anti-progestin activity.
About Arno Therapeutics
Arno Therapeutics is a clinical stage biopharmaceutical company
developing innovative products for the treatment of cancer.
Arno has exclusive worldwide rights to develop and market three
innovative anti-cancer product candidates. These compounds
are in clinical or preclinical development as product candidates to
treat hematologic malignancies and solid tumors. For more
information about the company, please
visit www.arnothera.com.
Forward-Looking Statements
This press release contains forward-looking statements that
involve substantial risks and uncertainties. These statements are
often, but not always, made through the use of words or phrases
such as "anticipates," "expects," "plans," "believes," "intends,"
and similar words or phrases. These forward-looking statements
include, without limitation, statements regarding the timing,
progress and anticipated results of the clinical development of
onapristone, statements regarding Arno's use and development of a
diagnostic test to identify patients with APR tumors, as well as
Arno's strategy, future operations, outlook, milestones, future
financial position, future financial results, plans and objectives.
We may not actually achieve these plans, intentions or expectations
and Arno cautions investors not to place undue reliance on our
forward-looking statements. Actual results or events could differ
materially from the plans, intentions and expectations disclosed in
the forward-looking statements we make. Various important factors
could cause actual results or events to differ materially from the
forward-looking statements that we make. Such factors include,
among others, risks that the results of clinical trials will not
support our claims or beliefs concerning the effectiveness of
onapristone or any of our other product candidates, our ability to
successfully develop a diagnostic to identify APR tumors, our
ability to finance the development of our product candidates,
regulatory risks, and our reliance on third party researchers and
other collaborators. Additional risks are described in the
company's Annual Report on Form 10-K for the year
ended December 31, 2012. Arno is providing this information as
of the date of this press release and does not undertake any
obligation to update any forward-looking statements as a result of
new information, future events or otherwise.
CONTACT: The Ruth Group
Lee Roth (investors)
lroth@theruthgroup.com
(646) 536-7012
Kirsten Thomas (media)
kthomas@theruthgroup.com
(646) 536-7014
Arno Therapeutics
Glenn Mattes
gm@arnothera.com
(862) 703-7176
Arno Therapeutics (CE) (USOTC:ARNI)
Historical Stock Chart
From May 2024 to Jun 2024
Arno Therapeutics (CE) (USOTC:ARNI)
Historical Stock Chart
From Jun 2023 to Jun 2024